10x Genomics Inc (NASDAQ: TXG) kicked off on Tuesday, down -0.44% from the previous trading day, before settling in for the closing price of $15.86. Over the past 52 weeks, TXG has traded in a range of $14.02-$57.90.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 35.76% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 36.20%. With a float of $99.61 million, this company’s outstanding shares have now reached $105.04 million.
In an organization with 1259 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 63.96%, operating margin of -36.65%, and the pretax margin is -36.92%.
10x Genomics Inc (TXG) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Health Information Services Industry. The insider ownership of 10x Genomics Inc is 17.33%, while institutional ownership is 81.65%. The most recent insider transaction that took place on Aug 22 ’24, was worth 152,053. In this transaction Chief Executive Officer of this company sold 6,749 shares at a rate of $22.53, taking the stock ownership to the 882,467 shares. Before that another transaction happened on Aug 22 ’24, when Company’s See Remarks sold 4,351 for $22.53, making the entire transaction worth $98,027. This insider now owns 345,704 shares in total.
10x Genomics Inc (TXG) Latest Financial update
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported -0.79 earnings per share (EPS), lower than consensus estimate (set at -0.46) by -0.33. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 36.20% per share during the next fiscal year.
10x Genomics Inc (NASDAQ: TXG) Trading Performance Indicators
Take a look at 10x Genomics Inc’s (TXG) current performance indicators. Last quarter, stock had a quick ratio of 4.42. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.01.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.02, a number that is poised to hit -0.23 in the next quarter and is forecasted to reach -1.03 in one year’s time.
Technical Analysis of 10x Genomics Inc (TXG)
Let’s dig in a bit further. During the last 5-days, its volume was 1.51 million. That was inferior than the volume of 1.69 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 60.83%. Additionally, its Average True Range was 1.02.
During the past 100 days, 10x Genomics Inc’s (TXG) raw stochastic average was set at 16.48%, which indicates a significant decrease from 64.24% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 121.74% in the past 14 days, which was higher than the 85.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.23, while its 200-day Moving Average is $27.78. However, in the short run, 10x Genomics Inc’s stock first resistance to watch stands at $16.15. Second resistance stands at $16.51. The third major resistance level sits at $16.87. If the price goes on to break the first support level at $15.43, it is likely to go to the next support level at $15.07. The third support level lies at $14.71 if the price breaches the second support level.
10x Genomics Inc (NASDAQ: TXG) Key Stats
The company with the Market Capitalisation of 1.90 billion has total of 120,491K Shares Outstanding. Its annual sales at the moment are 618,730 K in contrast with the sum of -255,100 K annual income. Company’s last quarter sales were recorded 153,100 K and last quarter income was -37,900 K.
